Cargando…

Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice

BACKGROUND: Transforming growth factor beta (TGF-β)-Smad2/3 is the major signaling pathway of fibrosis, which is characterized by the excessive production and accumulation of extracellular matrix (ECM) components, including collagen. Although the ECM is an essential component of skeletal muscle, fib...

Descripción completa

Detalles Bibliográficos
Autores principales: Kakutani, Naoya, Takada, Shingo, Nambu, Hideo, Matsumoto, Junichi, Furihata, Takaaki, Yokota, Takashi, Fukushima, Arata, Kinugawa, Shintaro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183133/
https://www.ncbi.nlm.nih.gov/pubmed/32334642
http://dx.doi.org/10.1186/s13395-020-00230-9
_version_ 1783526372736499712
author Kakutani, Naoya
Takada, Shingo
Nambu, Hideo
Matsumoto, Junichi
Furihata, Takaaki
Yokota, Takashi
Fukushima, Arata
Kinugawa, Shintaro
author_facet Kakutani, Naoya
Takada, Shingo
Nambu, Hideo
Matsumoto, Junichi
Furihata, Takaaki
Yokota, Takashi
Fukushima, Arata
Kinugawa, Shintaro
author_sort Kakutani, Naoya
collection PubMed
description BACKGROUND: Transforming growth factor beta (TGF-β)-Smad2/3 is the major signaling pathway of fibrosis, which is characterized by the excessive production and accumulation of extracellular matrix (ECM) components, including collagen. Although the ECM is an essential component of skeletal muscle, fibrosis may be harmful to muscle function. On the other hand, our previous studies have shown that levels of angiotensin II, which acts upstream of TGF-β-Smad2/3 signaling, is increased in mice with myocardial infarction (MI). In this study, we found higher skeletal muscle fibrosis in MI mice compared with control mice, and we investigated the mechanisms involved therein. Moreover, we administered an inhibitor based on the above mechanism and investigated its preventive effects on skeletal muscle fibrosis. METHODS: Male C57BL/6 J mice with MI were created, and sham-operated mice were used as controls. The time course of skeletal muscle fibrosis post-MI was analyzed by picrosirius-red staining (days 1, 3, 7, and 14). Mice were then divided into 3 groups: sham + vehicle (Sham + Veh), MI + Veh, and MI + lisinopril (an angiotensin-converting enzyme [ACE] inhibitor, 20 mg/kg body weight/day in drinking water; MI + Lis). Lis or Veh was administered from immediately after the surgery to 14 days postsurgery. RESULTS: Skeletal muscle fibrosis was significantly increased in MI mice compared with sham mice from 3 to 14 days postsurgery. Although mortality was lower in the MI + Lis mice than the MI + Veh mice, there was no difference in cardiac function between the 2 groups at 14 days. Skeletal muscle fibrosis and hydroxyproline (a key marker of collagen content) were significantly increased in MI + Veh mice compared with the Sham + Veh mice. Consistent with these results, protein expression of TGF-β and phosphorylated Smad2/3 in the skeletal muscle during the early time points after surgery (days 1–7 postsurgery) and blood angiotensin II at 14 days postsurgery was increased in MI mice compared with sham mice. These impairments were improved in MI + Lis mice, without any effects on spontaneous physical activity, muscle strength, muscle weight, and blood pressure. CONCLUSIONS: ACE inhibitor administration prevents increased skeletal muscle fibrosis during the early phase after MI. Our findings indicate a new therapeutic target for ameliorating skeletal muscle abnormalities in heart diseases.
format Online
Article
Text
id pubmed-7183133
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71831332020-04-28 Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice Kakutani, Naoya Takada, Shingo Nambu, Hideo Matsumoto, Junichi Furihata, Takaaki Yokota, Takashi Fukushima, Arata Kinugawa, Shintaro Skelet Muscle Research BACKGROUND: Transforming growth factor beta (TGF-β)-Smad2/3 is the major signaling pathway of fibrosis, which is characterized by the excessive production and accumulation of extracellular matrix (ECM) components, including collagen. Although the ECM is an essential component of skeletal muscle, fibrosis may be harmful to muscle function. On the other hand, our previous studies have shown that levels of angiotensin II, which acts upstream of TGF-β-Smad2/3 signaling, is increased in mice with myocardial infarction (MI). In this study, we found higher skeletal muscle fibrosis in MI mice compared with control mice, and we investigated the mechanisms involved therein. Moreover, we administered an inhibitor based on the above mechanism and investigated its preventive effects on skeletal muscle fibrosis. METHODS: Male C57BL/6 J mice with MI were created, and sham-operated mice were used as controls. The time course of skeletal muscle fibrosis post-MI was analyzed by picrosirius-red staining (days 1, 3, 7, and 14). Mice were then divided into 3 groups: sham + vehicle (Sham + Veh), MI + Veh, and MI + lisinopril (an angiotensin-converting enzyme [ACE] inhibitor, 20 mg/kg body weight/day in drinking water; MI + Lis). Lis or Veh was administered from immediately after the surgery to 14 days postsurgery. RESULTS: Skeletal muscle fibrosis was significantly increased in MI mice compared with sham mice from 3 to 14 days postsurgery. Although mortality was lower in the MI + Lis mice than the MI + Veh mice, there was no difference in cardiac function between the 2 groups at 14 days. Skeletal muscle fibrosis and hydroxyproline (a key marker of collagen content) were significantly increased in MI + Veh mice compared with the Sham + Veh mice. Consistent with these results, protein expression of TGF-β and phosphorylated Smad2/3 in the skeletal muscle during the early time points after surgery (days 1–7 postsurgery) and blood angiotensin II at 14 days postsurgery was increased in MI mice compared with sham mice. These impairments were improved in MI + Lis mice, without any effects on spontaneous physical activity, muscle strength, muscle weight, and blood pressure. CONCLUSIONS: ACE inhibitor administration prevents increased skeletal muscle fibrosis during the early phase after MI. Our findings indicate a new therapeutic target for ameliorating skeletal muscle abnormalities in heart diseases. BioMed Central 2020-04-25 /pmc/articles/PMC7183133/ /pubmed/32334642 http://dx.doi.org/10.1186/s13395-020-00230-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Kakutani, Naoya
Takada, Shingo
Nambu, Hideo
Matsumoto, Junichi
Furihata, Takaaki
Yokota, Takashi
Fukushima, Arata
Kinugawa, Shintaro
Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice
title Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice
title_full Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice
title_fullStr Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice
title_full_unstemmed Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice
title_short Angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice
title_sort angiotensin-converting-enzyme inhibitor prevents skeletal muscle fibrosis in myocardial infarction mice
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183133/
https://www.ncbi.nlm.nih.gov/pubmed/32334642
http://dx.doi.org/10.1186/s13395-020-00230-9
work_keys_str_mv AT kakutaninaoya angiotensinconvertingenzymeinhibitorpreventsskeletalmusclefibrosisinmyocardialinfarctionmice
AT takadashingo angiotensinconvertingenzymeinhibitorpreventsskeletalmusclefibrosisinmyocardialinfarctionmice
AT nambuhideo angiotensinconvertingenzymeinhibitorpreventsskeletalmusclefibrosisinmyocardialinfarctionmice
AT matsumotojunichi angiotensinconvertingenzymeinhibitorpreventsskeletalmusclefibrosisinmyocardialinfarctionmice
AT furihatatakaaki angiotensinconvertingenzymeinhibitorpreventsskeletalmusclefibrosisinmyocardialinfarctionmice
AT yokotatakashi angiotensinconvertingenzymeinhibitorpreventsskeletalmusclefibrosisinmyocardialinfarctionmice
AT fukushimaarata angiotensinconvertingenzymeinhibitorpreventsskeletalmusclefibrosisinmyocardialinfarctionmice
AT kinugawashintaro angiotensinconvertingenzymeinhibitorpreventsskeletalmusclefibrosisinmyocardialinfarctionmice